GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (STU:1A80) » Definitions » Cyclically Adjusted Price-to-FCF

Accelerate Diagnostics (STU:1A80) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Accelerate Diagnostics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Accelerate Diagnostics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics Cyclically Adjusted Price-to-FCF Chart

Accelerate Diagnostics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Accelerate Diagnostics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF falls into.



Accelerate Diagnostics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Accelerate Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Accelerate Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.429/131.7762*131.7762
=-0.429

Current CPI (Mar. 2024) = 131.7762.

Accelerate Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.751 100.560 -0.984
201409 -1.187 100.428 -1.558
201412 -0.975 99.070 -1.297
201503 -1.689 99.621 -2.234
201506 -2.065 100.684 -2.703
201509 -1.856 100.392 -2.436
201512 -2.188 99.792 -2.889
201603 -2.611 100.470 -3.425
201606 -2.657 101.688 -3.443
201609 -2.215 101.861 -2.866
201612 -2.378 101.863 -3.076
201703 -2.829 102.862 -3.624
201706 -2.332 103.349 -2.973
201709 -2.247 104.136 -2.843
201712 -2.157 104.011 -2.733
201803 -2.531 105.290 -3.168
201806 -2.973 106.317 -3.685
201809 -2.873 106.507 -3.555
201812 -2.349 105.998 -2.920
201903 -3.183 107.251 -3.911
201906 -2.290 108.070 -2.792
201909 -2.903 108.329 -3.531
201912 -2.313 108.420 -2.811
202003 -2.976 108.902 -3.601
202006 -1.602 108.767 -1.941
202009 -2.008 109.815 -2.410
202012 -1.486 109.897 -1.782
202103 -1.920 111.754 -2.264
202106 -1.299 114.631 -1.493
202109 -1.730 115.734 -1.970
202112 -1.598 117.630 -1.790
202203 -1.749 121.301 -1.900
202206 -1.613 125.017 -1.700
202209 -1.575 125.227 -1.657
202212 -0.935 125.222 -0.984
202303 -1.271 127.348 -1.315
202306 -0.920 128.729 -0.942
202309 -0.580 129.860 -0.589
202312 -0.495 129.419 -0.504
202403 -0.429 131.776 -0.429

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Accelerate Diagnostics  (STU:1A80) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Accelerate Diagnostics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Accelerate Diagnostics (STU:1A80) Business Description

Traded in Other Exchanges
Address
3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714
Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Accelerate Diagnostics (STU:1A80) Headlines

No Headlines